BR1400-3 not checked
Boryung Pharmaceutical Co., Ltd
FollowEvery change as it happens, and a Monday email
Trials
1 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Essential Hypertension
- Main trialPhase 2
- “The objective of this clinical trial is to evaluate the antihypertensive efficacy and safety of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 with essential hypertension.”In the company’s words, NCT07373613 on ClinicalTrials.gov
Other drugs for Essential Hypertension
- BR1019Boryung Pharmaceutical Co., Ltd · Phase 3
- Valsartan Oral SolutionShandong New Time Pharmaceutical Co., LTD · Phase 3
- AD-227AAddpharma Inc. · Phase 3
- AD-227BAddpharma Inc. · Phase 3
- QR12000Wuhan Createrna Science and Technology Co., Ltd · Phase 3
- Sacubitril∙ValsartanChong Kun Dang Pharmaceutical · Phase 3
Coming up1
- 1 Feb 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | 1 Feb 2027 | A Study of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential Hypertension | |
| Phase 1Completed | 8 Oct 2024 | A Study to Evaluate the Pharmacokinetic, Pharmacodynamic Characteristics and the Safety After Administration by Doses of BR1400-1, BR1400-2, BR1400-3 in Healthy Adult Volunteers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026